KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$190.0 million.

  • Emergent BioSolutions' Cash from Financing Activities rose 91.18% to -$15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 88.05%. This contributed to the annual value of -$190.0 million for FY2024, which is 64.53% up from last year.
  • Per Emergent BioSolutions' latest filing, its Cash from Financing Activities stood at -$190.0 million for FY2024, which was up 64.53% from -$535.7 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Cash from Financing Activities high stood at $481.2 million for FY2022, and its period low was -$535.7 million during FY2023.
  • For the 3-year period, Emergent BioSolutions' Cash from Financing Activities averaged around -$81.5 million, with its median value being -$190.0 million (2024).
  • Per our database at Business Quant, Emergent BioSolutions' Cash from Financing Activities crashed by 302.88% in 2021 and then surged by 441.28% in 2022.
  • Emergent BioSolutions' Cash from Financing Activities (Yearly) stood at $69.5 million in 2020, then tumbled by 302.88% to -$141.0 million in 2021, then surged by 441.28% to $481.2 million in 2022, then plummeted by 211.33% to -$535.7 million in 2023, then spiked by 64.53% to -$190.0 million in 2024.